Patent Expiry of Blockbuster Drugs to Lead to Decline in Global Dyslipidemia Drugs Market

Dyslipidemia is a chronic metabolic ailment characterized by the presence of lipids in abnormal amounts in the blood. It is triggered by the increasing concentration of high-density lipoproteins (HDL), low-density lipoproteins (LDL), constituting an abnormal increase in overall triglyceride levels. For dyslipidemia treatment, medical professionals often prescribe a range of therapeutics that include cholesterol absorption inhibitors, bile acid resins, statins, omega-3 fatty acid derivatives, niacins, and fibric acid derivatives. Additionally, therapies such as ezetimibe and statins (Vytorin), statin and fibric acid analogs, statins (Advicor), niacins, and others are administered to ensure effective treatment of dyslipidemia. 

Impending Patent Expiry of Blockbuster Drugs to Impact the Market Negatively

The global market for dyslipidemia drugs gains impetus from the increasing incidence of dyslipidemia in developed regions such as Europe and North America. The growing prevalence of the syndrome is also noted in a few developing economies in Asia Pacific, which further boosts the global dyslipidemia drugs market. Despite witnessing a rising demand from major economies worldwide, the patent expiry of blockbuster drugs such as Crestor, Zetia, and Vytorin will have a profound negative impact on the market’s growth trajectory. 

In its latest report, Transparency Market Research pegs the overall value of the global dyslipidemia drugs market at US$17.8 bn in 2014. However, at a steadily declining CAGR of -10.30% between 2015 and 2023, the overall valuation of the market could drop to as low as US$6.9 bn by the end of 2023. 

Common Risk Factors Leading to Dyslipidemia

Dyslipidemia is common in people suffering from diabetes and/or hypothyroidism. Among women, polycystic ovary syndrome is a common condition leading to dyslipidemia if left untreated for a long period. 

The common metabolic syndrome associated with dyslipidemia includes the following risk factors: 

Elevated waist circumference among both men and women. For men, it could be greater than or equal to 40 inches, while in women, it could be greater than or equal to 35 inches. 
Reduced HDL cholesterol is also often associated with dyslipidemia. For men, it could be less than 40 mg/dL and for women, HDL falling below 50 mg/dL can be a major risk factor.
Elevated triglycerides level greater than or equal to 150 mg/dL is one of the major risk factors associated with dyslipidemia.  
Elevated blood pressure greater than or equal to 135/85 mm Hg.
High blood glucose level is a crucial risk factor. For instance, a fasting glucose level of greater than or equal to 100 mg/dL can lead to dyslipidemia. 

For all the aforementioned conditions, administering dyslipidemia drugs at prescribed doses is essential to keep dyslipidemia and the associated health risks at bay. 

Expanding Population of People with High Cholesterol Level Boosts North America Dyslipidemia Drugs Market

The American Heart Association (AHA) conducted a survey in 2013, according to which approximately 98.9 million people in the U.S. aged 20 years and above have been diagnosed with high blood cholesterol level of more than 200 mg/dL. Almost 31.9 million people among the aforementioned demographic have blood cholesterol levels of 240 mg/dL or more.  Owing to this, the demand for dyslipidemia drugs is very high in the U.S. While the impending patent expiry of blockbuster drugs creates bottlenecks for enterprises operating in the North America dyslipidemia market, which held the dominant share of the global market in 2014, favorable government approval policies and high incidence of diabetes will boost the market in the region. 

Europe emerged as the second largest market for dyslipidemia drugs in 2014 and accounted for over 25% of the global dyslipidemia drugs market. 


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports